Journal article

Publication year: 2020

Pages: 518-529

Journal: Nervenarzt

Volume number: 91

Issue number: 6

ISSN: 0028-2804

eISSN: 1433-0407

Open access status: Hybrid

DOI Link: https://doi.org/10.1007/s00115-020-00919-8

Publisher: Springer

Abstract: 
Background Spinal muscular atrophy (SMA) is a severe, life-limiting neurodegenerative disease. A disease-modifying and approved therapy with nusinersen has been available in Germany since July 2017. Gene therapies offer another promising treatment option through a once in a lifetime administration. In May 2019 a gene replacement therapy for the treatment of SMA was approved for the first time by the U.S. Food and Drug Administration (FDA). An application for approval in Europe has been submitted and is currently pending. Objective This consensus paper was compiled at the invitation of the German Society for Muscular Diseases (DGM) with the participation of all potential German neuromuscular treatment centers, the German section of the Society for Pediatric Neurology (GNP) and with the involvement of the medical scientific advisory board of the DGM. The aim was to define and establish the necessary prerequisites for a safe and successful application of the new gene replacement therapy in clinical practice. Conclusion Gene replacement therapy with onasemnogene abeparvovec has the potential to significantly influence the course of SMA. Long-term data on sustainability of effects and possible adverse effects of gene replacement therapy are not yet available. The application of this innovative therapy must be carried out in specialized and appropriately qualified treatment centers under strict safety conditions. This article makes suggestions for the necessary framework conditions and gives recommendations for a systematic pretreatment and posttreatment assessment schedule under gene therapy. The effectiveness and safety of the therapy should be systematically documented in an industry-independent and disease-specific register.

Harvard Citation style: Ziegler, A., Wilichowski, E., Schara, U., Hahn, A., Mueller-Felber, W., Johannsen, J., et al. (2020) Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM), Nervenarzt, 91(6), pp. 518-529. https://doi.org/10.1007/s00115-020-00919-8

APA Citation style: Ziegler, A., Wilichowski, E., Schara, U., Hahn, A., Mueller-Felber, W., Johannsen, J., von der Hagen, M., von Moers, A., Stoltenburg, C., Saffari, A., Walter, M., Husain, R., Pechmann, A., Koehler, C., Horber, V., Schwartz, O., & Kirschner, J. (2020). Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM). Nervenarzt. 91(6), 518-529. https://doi.org/10.1007/s00115-020-00919-8